Careers  |  Sign In  |  Register

FDA Approves Device to Resynchronize Heart

The FDA has approved a new device, Viva, that is “used to resynchronize the beating of the heart and reduce hospitalizations for heart failure.” An article in Bloomberg News explains that Viva, a product of Medtronic Inc., does not require doctors to recalibrate the device as the “implanted device uses an algorithm to coordinate the heart’s 100,000 contractions each day, adjusting to varying demands of the body as the user goes through regular daily activities.” The device also has longer battery life than older models, and “Significantly more heart-failure patients responded to treatment and they were 21 percent less likely to be hospitalized in the first year than those with older devices.”

Read it in Bloomberg News.